FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2026 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

XBIZ 2027 Host Hotel Sold Out, Nearby Room Block Added

As preparations continue for XBIZ 2027, the event's official host hotel, JW Marriott L.A. LIVE, has now completely sold out.

Orion Debuts 'Ride On 2' Vibepad

Orion Wholesale has introduced its new Ride On 2 vibepad.

Report: TDR Capital Reaches $460M Deal to Acquire Lovehoney Group

Private equity firm TDR Capital has reached an agreement to acquire Lovehoney Group in a deal valued at approximately €400 million ($460 million), according to a report by Sky News.

Wild Brands to Unveil 1st Product Collection at XBIZ Expo

Sexual wellness company Wild Brands will introduce its debut product collection at XBIZ Expo in January.

EngErotics Launches Capital Raise Through Campaign on CataCap

Sexual wellness brand EngErotics has launched a campaign to raise capital for expansion on the CataCap philanthropic investment platform.

PinkCherry Relaunches Wholesale Division

Pleasure distributor PinkCherry has relaunched its wholesale division.

Beisar Introduces 'PhoenixGP' Unicorn-Inspired Thrusting Vibe

Beisar has debuted its new PhoenixGP unicorn-spired thrusting, vibrating dildo.

Orion Adds New Stocking Styles to 'Cottelli Legwear' Line

Orion Wholesale has expanded its Cottelli Legwear collection with several new stocking styles.

Xgen Expands 'Bare by Baci' Wellness Collection

Xgen Products has expanded its Bare by Baci line of wellness products with five new additions, comprising two pleasure balms, two body glow lotions, and a pheromone-infused body mist.

Full Circle Expands 'Be Savage' Lingerie Line

Full Circle has added 77 new items to its Be Savage lingerie collection.

Show More